Pharmabiz

Tolerance Bio licenses clinical-stage anti-IL-33 monoclonal antibody from Tanabe Pharma to expand thymus-focused clinical pipeline

Tolerance Bio licenses clinical-stage anti-IL-33 monoclonal antibody from Tanabe Pharma to expand thymus-focused clinical pipeline: Philadelphia, Pennsylvania Tuesday, September 2 ...

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance ...
MarketScreener

Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine Trial

Announces Results of VYD2311 Studies DECLARATION And LIBERTY CI(NasdaqGM:IVVD) added to Russell 2000 Index CI Jun. 29 Invivyd, Inc.(NasdaqGM:IVVD) added to Russell Microcap Value Benchmark Index CI ...

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

SHELTON, CT / ACCESS Newswire / September 29, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with ...
MarketScreener

BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 70 years of ...